Equities

Kewaunee Scientific Corp

Kewaunee Scientific Corp

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kewaunee Scientific Corporation is engaged in designing, manufacturing, and installation of laboratory, healthcare and technical furniture products. The Company’s products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, ultralow freezers, and epoxy resin work surfaces and sinks. Its segments include Domestic and International. The Domestic segment designs, manufactures, and installs scientific and technical furniture. The International segment consists of foreign subsidiaries. The Company's products are sold primarily through purchase orders and contracts submitted by customers through its dealers and its subsidiaries, and a national distributor. It has three manufacturing facilities that are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets.

  • Revenue in USD (TTM)202.31m
  • Net income in USD18.47m
  • Incorporated1970
  • Employees1.01k
  • Location
    Kewaunee Scientific Corp2700 W Front StSTATESVILLE 28677United StatesUSA
  • Phone+1 (704) 873-7202
  • Fax+1 (302) 674-5266
  • Websitehttps://kewaunee.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
KEQU:NMQ since
announced
Transaction
value
NuAire IncDeal completed01 Nov 202401 Nov 2024Deal completed20.08%55.00m
Data delayed at least 15 minutes, as of Nov 13 2024 20:49 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.